The overview discusses 58 peptides in different clinical phases, indicating a robust pipeline of peptide therapies focusing on PPIs. Brief protein and peptide therapeutics produced by genetic code enlargement even have a brief half-life as a consequence of their very poor pharmacokinetics, which include rapidly serum degradation and speedy elimi